Expert Opinion on Investigational Drugs

In light of the failure of Right to Try bill in The House, some background here: "Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits" bit.ly/2pj6JIM by @LiaTsimberidou et al from @MDAndersonNews #rightotry #openaccess

Cefiderocol, a cephalosprin which targets siderophore uptake, suggested to have the potential to become first-line therapy for our most aggressive and lethal multidrug-resistant Gram-negative pathogens ncbi.nlm.nih.gov/pubmed/29318906

Paper on discontinued #Alzheimer's drugs is particularly relevant today: "Why are they failing? Is the treatment of symptomatic dementia too late? Are the therapeutic targets incorrect? Are the clinical methodologies imprecise, misleading, or inaccurate?" bit.ly/2qPIwNs twitter.com/bbchealth/stat…

Great to see @EnriqueSoto8 and @smlichtman_md's editorial "Considerations for clinical trial design in older adults with cancer" being featured in the #HemeAging session at last month's American Society of Hematology 2017 Annual Meeting #ASH17 #GeriOnc twitter.com/Kristel_GT/sta…

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations tandfonline.com/doi/full/10.10…

Endoglin and ALK1 as therapeutic targets for hereditary hemorrhagic telangiectasia written by Ruiz-Llorente et al (@CIBERER) is Open Access and available here at Expert Opinion on Therapeutic Targets: bit.ly/2zK6cFL

Interesting perspective on an emerging field - Investigational PD-1 inhibitors for advanced non-small lung cancer, new players in a shifting paradigm. Free to read editorial by Ghanem et al from @NorthwellHealth, available here: bit.ly/2zKF75n

Editorial by @EnriqueSoto8 & @smlichtman_md - "Considerations for clinical trial design in older adults with cancer" is free to view online! twitter.com/EnriqueSoto8/s…

BI 695502, US- & EU-approved Avastin showed 3-way bioequivalence with similar safety profile. Free access to trial - bit.ly/2vsXo36

SLEEP disturbances & severe STRESS as GLIAL activators: psychoneuroimmunology model explaining central sensitization ncbi.nlm.nih.gov/pubmed/28685641

Phase I trial assessing the bioequivalence of BI 695502, a bevacizumab biosimilar candidate. Free to access - bit.ly/2vsXo36

Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015 bit.ly/2rJcEts

Review - Preclinical to Phase II Amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease bit.ly/2oMgkF4

Review article - MERS-CoV spike protein: a key target for antivirals. Free to view until end of April. bit.ly/2oHvzAh

Read about accessory gene regulator-1 as a therapeutic target for C. difficile infection in this free editorial: bit.ly/2orfVJp

Review article - Drugs in clinical development for the treatment of amyotrophic lateral sclerosis (ALS) bit.ly/2oDnnnc

@TheScientistLLC The MERS-CoV spike protein review that is referred to in this article is free to access for April! bit.ly/2oHvzAh twitter.com/TheScientistLL…

Read about the latest investigational drugs for head and neck #cancer in this recently published #free #editorial bit.ly/2lAzejY

An interesting new review recently published in Expert Opinion on Therapeutic Targets twitter.com/ExpertOpinion/…

Read this #free to view #editorial on KCC3 cotransporter as a therapeutic target for peripheral neuropathy... bit.ly/2lsEJOJ